Dable Habib J 4

What Happened

• Dable Habib J, a director of Tyra Biosciences, was granted an equity award covering 44,400 shares (reported as a derivative) on April 16, 2026. The Form 4 lists an acquisition price of $0.00 (award/grant code A), so no cash was paid at grant. This is a compensatory equity grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-04-16; Form 4 filed: 2026-04-20 (timely filed).
• Reported amount: 44,400 shares (derivative award) at $0.00 per share.
• Shares owned after transaction: not specified in the filing.
• Footnote: the award vests 1/36th monthly beginning April 16, 2026, subject to continuous service (i.e., a 36-month monthly vesting schedule).
• Transaction code: A = Award/Grant (not a sale or purchase); no 10b5-1 or tax-withholding notes disclosed.

Context

• This grant is a standard director compensation event. Because it's a derivative award subject to vesting, the director does not yet have fully vested, unrestricted shares and has not exercised any options or received cash. Such grants are common and do not by themselves indicate immediate buying or selling intent.